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Newborn screening (NBS) for medium-chain acyl-CoA dehydrogenase deﬁciency (MCADD) revealed a higher
birth prevalence and genotypic variability than previously estimated, including numerous novel missense
mutations in the ACADM gene. On average, these mutations are associated with milder biochemical pheno-
types raising the question about their pathogenic relevance. In this study, we analyzed the impact of 10
ACADM mutations identiﬁed in NBS (A27V, Y42H, Y133H, R181C, R223G, D241G, K304E, R309K, I331T and
R388S) on conformation, stability and enzyme kinetics of the corresponding proteins. Partial to total rescue
of aggregation by co-overexpression of GroESL indicated protein misfolding. This was conﬁrmed by acceler-
ated thermal unfolding in all variants, as well as decreased proteolytic stability and accelerated thermal inac-
tivation in most variants. Catalytic function varied from high residual activity to markedly decreased activity
or substrate afﬁnity. Mutations mapping to the b-domain of the protein predisposed to severe destabilization.
In silico structural analyses of the affected amino acid residues revealed involvement in functionally relevant
networks. Taken together, our results substantiate the hypothesis of protein misfolding with loss-of-function
beingthecommonmolecularbasisinMCADD.Moreover,considerablestructuralalterationsinallanalyzedvar-
iantsdonotsupporttheviewthatnovelmutationsfoundinNBSbearalowerriskofmetabolicdecompensation
than that associated with mutations detected in clinically ascertained patients. Finally, the detailed insight into
howACADMmissensemutationsinducelossofMCADfunctionmayprovideguidanceforriskassessmentand
counseling of patients, and in future may assist delineation of novel pharmacological strategies.
INTRODUCTION
Newborn screening (NBS) for medium-chain acyl-CoA dehy-
drogenase deﬁciency (MCADD; MIM #201450) by tandem-
mass spectrometry has successfully been implemented in
many countries worldwide (1). MCADD revealed a notably
higher birth prevalence (1:15000) than previously estimated
(1–3) and nowadays is the disorder most frequently diagnosed
in NBS, together with phenylketonuria (4). The disease leads
to a defect in mitochondrial b-oxidation of fatty acids. Patients
show a decreased ability to withstand catabolic stress and risk
coma and death due to hypoketotic hypoglycemia during
prolonged fasting or intercurrent illness. In undiagnosed
patients, the disorder shows a signiﬁcant morbidity and mor-
tality. Approximately 20% of patients die during their ﬁrst
metabolic crisis and 40% of the survivors show sustained
neurological impairment (5–7). Once diagnosed, however,
adverse effects can be prevented by avoidance of fasting
during episodes of catabolic stress. Thus, MCADD is the dis-
order thought to most justify early detection by NBS (4).
In patients diagnosed after metabolic decompensation, the
mutation K304E (c.985A.G) (ACADM gene; OMIM
#607008) has been shown to account for 90% of defective
alleles (8) and therefore is considered to be a severe mutation
associated with a high risk of clinical manifestation (9).
†The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
 To whom correspondence should be addressed. Tel: þ49 89 5160 2746; Fax: þ49 89 5160 7792; Email: ania.muntau@med.uni-muenchen.de
# 2009. The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original worki s
properly cited.
Human Molecular Genetics, 2009, Vol. 18, No. 9 1612–1623
doi:10.1093/hmg/ddp079
Advance Access published on February 18, 2009K304E and few other missense mutations identiﬁed in symp-
tomatic patients were previously shown to induce protein mis-
folding and aggregation (10–17).
MCADD patients identiﬁed by NBS show a considerably
wider genotypic heterogeneity with the mutation K304E being
less prevalent. Numerous novel mutations were unraveled
including a second prevalent mutation, Y42H (c.199T.C)
(3,18–20). After diagnosis, patients carrying these allelic var-
iants follow disease management plans to avoid metabolic
crises. Thus, the natural course of MCADD associated with
this new group of mutations is unlikely to be witnessed. On
average, these patients express lower disease markers (octanoyl-
carnitine and related acylcarnitine ratios in blood) than observed
in homo- or heterozygosity for K304E (3,18,20). However, the
different genotypes show a high variability of values, and it is
generally accepted that the biochemical phenotype does not
allow for a reliable assessment of the risk associated with the
single mutations. Insights into the molecular effects of the
mutations on the corresponding protein would be helpful to esti-
mate their pathogenic relevance. Yet, experimental data on the
molecularconsequencesofthevariousnovelmissensemutations
identiﬁed in NBS is scarce and mainly refers to the mild
temperature-sensitive Y42H mutation (18,21,22). The aim of
this study, therefore, was to elucidate the impact of mutations
found in presymptomatic newborns on conformation, stability
and catalytic function of the variant MCAD proteins.
MCAD is a member of the acyl-CoA dehydrogenase
(ACAD) family of ﬂavoproteins, which catalyzes the ﬁrst step
of the mitochondrial b-oxidation of medium-chain fatty acids.
The ACAD family comprises nine known members, ﬁve of
which are involved in fatty acid oxidation, four in amino acid
oxidation (23). Each subunit of the homotetrameric MCAD
enzyme is composed of three structural domains of approxi-
mately equal size, namely the N-terminal a-domain (residues
1–129), the b-domain (residues 130–239) and the C-terminal
a-domain (residues 240–396). The N- and C-terminal
domains predominantly consist of densely packed a-helices,
which shape the core of the tetramer. The middle b-domains
are exposed at the surface of the molecule and comprise two
orthogonal b-sheets. The catalytic centers consisting of the
binding sites for the substrate and the natural cofactor ﬂavin
adenine dinucleotide (FAD) are mainly formed by the interface
betweentheb-domainandtheC-terminala-domain.Thethree-
dimensional (3D) structure is a tetrahedral arrangement of
a dimer of dimers with an overall diameter of 90A ˚. The
interactions between the two monomers forming a dimer are
extensive and involve the FAD binding site, whereas between
the two dimers predominantly helix–helix interactions are
found, similar to a four-helix bundle structure (23).
In this study, we characterized ten MCAD variants with
single amino acid substitutions spread over the protein
derived from mutations previously reported from the NBS in
Bavaria, Germany, including the two prevalent mutations
Y42H and K304E (3). We established a high-yield puriﬁcation
protocol for recombinant prokaryotic expression of wild-type
and variant MCAD proteins using a maltose binding
protein (MBP)-tag. The puriﬁed proteins were subsequently
characterized with respect to oligomerization, enzyme kin-
etics, proteolytic stability, thermal inactivation and thermal
unfolding. Impressively, all variants showed alterations of
protein function, yet in heterogeneous ways. Catalytic function
varied from high residual activity to markedly decreased
activity and severe alteration of substrate afﬁnity. We
observed aggregation with partial rescue by co-overexpression
of chaperonins, decreased proteolytic stability and accelerated
thermal inactivation in most variants. Thermal unfolding was
facilitated in all variants. Data on proteolytic and thermal stab-
ility revealed that conformational changes and destabilization
are most pronounced in mutations mapping to the b-domain of
the protein. These results substantiate the hypothesis of protein
misfolding with loss-of-function being the common molecular
basis in MCADD. The hypothesis holds true not only for the
common variant K304E, but also for mutations derived from
presymptomatic patients.
RESULTS
Disturbed oligomerization is partially rescued
by co-overexpression of GroESL
Wild-type and ten variant forms of MCAD (Fig. 1 and Table 1)
were puriﬁed by afﬁnity chromatography and subsequent
size-exclusion chromatography (SEC) to analyze the oligo-
meric states of the expressed fusion proteins (Fig. 2). Wild-type
MCAD was eluted in the tetrameric form with an almost negli-
gible amount of aggregates (,1%), whereas MCAD variants
showed a markedly decreased expression of soluble protein
consistent with proneness to aggregation and degradation of
misfolded protein. Only one variant (R388S) showed an
elution proﬁle identical to wild-type. The remaining variants
revealed severely disturbed oligomerization consisting of (i)
small amounts of tetramers (Y42H, D241G, R309K) with or
without high molecular weight aggregates, (ii) exclusively
high molecular weight aggregates (A27V, K304E, I331T) or
(iii) small amounts of protein fragments of various molecular
weights (Y133H, R181C) (Fig. 2A). No monomers or dimers
were observed with any of the variants. R223G was expressed
Figure 1. Structural localization of MCAD missense mutations analyzed. The
MCAD monomer, shown as a ribbon representation, is composed of three
structural domains: the N-terminal a-helix domain (residues 1–129, red),
the b-sheet domain (residues 130–239, blue) and the C-terminal a-helix
domain (residues 240–396, green). Amino acid residues affected by mutations
are shown as stick models with carbon atoms in white, oxygen atoms in red
and nitrogen atoms in blue.
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not shown) and could not be subjected to SEC.
Tetramer formation was partially rescued by co-overexpres-
sion of the chaperonins GroES and GroEL. Co-overexpressing
GroESL, seven variants (A27V, Y42H, Y133H, R181C,
D241G, K304E, R309K) showed oligomerization proﬁles
similar to that of wild-type with only small amounts of aggre-
gates (5–7%) (Fig. 2B). Co-overexpression of chaperonins did
not enhance protein folding for the two variants I331T and
R223G.
In summary, we observed disturbed oligomerization with
aggregation and/or degradation in nine of 10 MCAD variants
analyzed. Our results conﬁrm that ACADM mutations can com-
promise protein folding, but misfolding can be mitigated to
variousextentbyincreasingtheamountofavailablechaperonins.
Variant MCAD proteins show different patterns
of enzyme kinetic parameters
Kinetic analyses using the ferricenium ion as an electron
acceptor were performed for wild-type and puriﬁed MCAD
variants (Table 2). All variants displayed Michaelis–Menten
behavior. Enzyme activity with respect to Vmax was compar-
able to wild-type in variants Y42H, R181C and R309K.
Reduced maximal activities were found in variants A27V
(38% of wild-type), D241G (48%) and K304E (46%).
Variant Y133H showed the most pronounced reduction in
activity (3.5%), but still followed Michaelis–Menten kinetics.
Vmax of wild-type, Y42H, and K304E are in line with the pre-
viously reported data (14,21,24).
For most of the variants, the apparent afﬁnity to the sub-
strate octanoyl-CoA was not or only slightly reduced. Only
R388S showed an excessively decreased substrate afﬁnity
with a 100-fold increase in Km (51.9 mM). This variant
showed a 2.5-fold increase in Vmax. However, the apparently
high activity is of no physiological relevance, since it would
require supraphysiological concentrations of substrate to
achieve it.
Km-values displayed in this study are 10-fold lower
compared with previously reported data (14,21,24). This
Figure 2. Disturbed oligomerization of variant MCAD proteins is partially
rescued by co-overexpression of GroESL. Oligomerization proﬁles of wild-
type (WT) and variant MCAD proteins were determined by size-exclusion
chromatography. Soluble high molecular weight aggregates (A) eluted at
volumes of 45–47 ml, tetramers (T) at 58–62 ml. No dimers or monomers
were observed with any of the variants. Elution volumes of .85 ml contained
fragments (F) of degraded MCAD or MBP. (A) Proﬁles without
co-overexpression of GroESL. Wild-type (WT) and R388S almost exclusively
eluted as tetramers. All other variants eluted as high molecular weight aggre-
gates or low molecular weight fragments with only three variants (Y42H,
D241G and R309K) showing small peaks of tetrameric MCAD. Aggregates
and degradation products of Y133H and R181C comprised various molecular
weights spread all over the chromatogram. (B) Proﬁles with co-overexpression
of GroESL. Variants A27V, Y42H, Y133H, R181C, D241G, K304E and
R309K showed a rescue of tetramer formation with only small amounts of
aggregates. Only for variant I331T, tetramer formation could not be restored.
Note: for WT, the chromatogram without co-overexpression of GroESL is
depicted.













aReference sequence: GenBank accession no. M16827.1. Nucleotide
numbering starts with A of the ATG initiation codon as þ1.
1614 Human Molecular Genetics, 2009, Vol. 18, No. 9observation might be an effect of correcting our measurements
for background ferricenium reduction, correcting octanoyl-
CoA concentrations for oxidizable substrate (see Materials
and Methods) and optimizing the assay for sensitive and
short duration measurements. However, the scale of the
reported differences between Km-values of wild-type, Y42H
and K304E is well comparable.
Taken together, the MCAD variants analyzed showed
different patterns of kinetic parameters: (i) activity compar-
able to wild-type, (ii) reduced and markedly reduced
maximal activity and (iii) an excessive decrease in afﬁnity
to octanoyl-CoA as a substrate.
Susceptibility to proteinase K is increased
Limited proteolysis is used for probing protein conformation
and folding kinetics. It can provide important information on
local unfolding and the equilibrium between the native state
oligomeric protein and its folding intermediates, since mis-
folded proteins are more susceptible to degradation by pro-
teases (25). To this aim, MCAD proteins were probed with
proteinase K, because its proteolysis is not limited to sequence
speciﬁcity but by stereochemistry and ﬂexibility of the protein
substrate. The proteolytic stability of wild-type and variant
MCAD proteins was analyzed by determination of the
half-lives, indicating the velocity of degradation, and the pla-
teaus of degradation, indicating the residual amount of protein
not susceptible to proteolysis (Table 3). Five variants (Y133H,
R181C, D241G, R309K and R388S) showed reduced
half-lives compared to wild-type, two of which reached stat-
istical signiﬁcance (Y133H and R309K). The plateaus of
degradation, however, were signiﬁcantly decreased in 4 of
these variants (Y133H, R181C, D241G and R309K). This
ﬁnding was most pronounced in variants Y133H and D241G
with residual protein amounts of 10 and 8%, respectively.
Notably, the plateau of degradation of the wild-type protein
was found to be 70%, indicating that at the assay conditions
(378C, 120 min) 30% of the wild-type protein is unfolded.
This ﬁnding reﬂects the thermal sensitivity of the MCAD
protein, which is additionally inﬂuenced by the protein con-
centrations used in the assay (21).
The decreased proteolytic stability of the variants compared
to wild-type is in line with the hypothesis of an altered folding
equilibrium shifted towards folding intermediates and destabi-
lization due to local protein unfolding.
Resistance of catalytic function against thermal
stress is reduced
We assessed the thermal effect on activity of wild-type and
variant MCAD proteins over a range of 25–558C. The mid-
point of thermal inactivation (T1/2), i.e. the temperature at
50% residual activity, was monitored by determination of
the residual activity at different temperatures. Near the mid-
point of denaturation of the wild-type (44.58C), kinetic stab-
ility expressed as half-lives (t1/2) was determined at 418C
(Fig. 3 and Table 4). A signiﬁcant reduction of T1/2 compared
with wild-type was found in all MCAD variants analyzed
except for K304E and R388S. Alterations were most pro-
nounced in Y133H (33.68C), R181C (34.38C) and D241G
(33.98C). These three variants also showed signiﬁcantly
decreased half-lives of 6.1 min (Y133H), 6.8 min (R181C)
and 9.7 min (D241G) when subjected to thermal stress as a
function of time (wild-type 20.0 min). The differences
among wild-type, Y42H and K304E with respect to T1/2 are
in line with the previously published data (14,18,21,26).
These observations indicate that temperature has a signiﬁ-
cant impact on catalytic function in variant MCAD proteins.
Notably, these effects are detectable at physiologically rel-
evant temperatures.
Thermal stress induces accelerated denaturation
To determine aberrant folding of MCAD with respect
to ground state hydrophobicity and thermal denaturation,
we performed 8-anilino-1-naphtalenesulfonic acid (ANS)








WT 31.2 6.6 70.1 5.8
A27V 34.5 2.8 ns 57.6 3.7 ns
Y42H 41.2 4.0 ns 56.8 10.6 ns
Y133H 7.2 0.2 ,0.05 10.0 3.6 ,0.01
R181C 29.4 8.7 ns 33.4 6.0 ,0.01
D241G 23.9 3.8 ns 8.2 2.5 ,0.01
K304E 30.7 7.3 ns 61.6 5.0 ns
R309K 7.7 2.7 ,0.05 47.6 1.9 ,0.01
R388S 19.2 7.30 ns 52.3 1.2 ns
Stability of wild-type (WT) and variant MCAD proteins against limited
proteolysis by proteinase K. The velocity of degradation (t1/2) was
assessed using a low protease:substrate ratio (1:25). The amount of protein
not susceptible to proteolysis (plateau) was determined at a higher
protease:substrate ratio (1:1). The calculated half-lives (t1/2) are given in
minutes, plateaus of degradation in per cent, both with corresponding
standard errors of the mean (SEM) of n ¼ 3 independent experiments.
Signiﬁcances for the differences between wild-type and the variants were
calculated by one-way ANOVA and a Dunnett’s post test. (ns, not
signiﬁcant).











WT 0.4 0.04 37.1 1.49
A27V 0.5 0.11 14.1 1.16
Y42H 0.7 0.10 35.4 3.00
Y133H 0.7 0.11 1.3 0.13
R181C 0.9 0.11 41.5 0.77
D241G 0.8 0.23 17.7 1.43
K304E 0.6 0.29 17.0 2.08
R309K 0.7 0.11 32.0 0.92
R388S
a 51.9 12.67 88.2 13.54
Steady-state kinetic parameters of wild-type (WT) and variant tetrameric
MCAD proteins. Maximum activities (Vmax) and apparent substrate
afﬁnities (Km) of octanoyl-CoA oxidation were determined by Michaelis–
Menten kinetics using a substrate range of 0–20 mM.
aEnzyme kinetic parameters determined at 0–150 mM octanoyl-CoA.
bStandard error of the mean of n ¼ 3 independent experiments.
Human Molecular Genetics, 2009, Vol. 18, No. 9 1615ﬂuorescence experiments. The use of the hydrophobic ﬂuoro-
phore ANS allowed monitoring of overall unfolding events,
since it binds to hydrophobic groups of the denaturing
protein showing a high quantum yield in its bound state, but
not when solved in aqueous buffers (27). ANS ﬂuorescence
analysis of tetrameric wild-type MCAD revealed a transition
midpoint (Tm1/2) between folded and unfolded state of
52.68C. This is in agreement with previous results obtained
by circular dichroism (16).
Figure 4A shows ANS ﬂuorescence proﬁles upon thermal
denaturation of wild-type, K304E and two severely distorted
variants. In variant Y133H, a considerably (20-fold) elevated
ground state ﬂuorescence signal at 258C was detected in com-
parison with wild-type. This ﬁnding indicates an increased
hydrophobicity due to partial protein unfolding even without
the application of thermal stress. The same was found in
R181C and K304E, but to a much lesser extent. Upon
thermal denaturation, for all MCAD variants the transition
from the native state to the unfolded state occurred at signiﬁ-
cantly lower temperatures than in the wild-type (Fig. 4B and
Table 5). The variants Y133H and R181C showed the most
pronounced alterations with Tm1/2 of 42.2 and 40.08C, respect-
ively. In addition to the marked left-shift of the curve, Y133H
revealed a steeper slope of the curve indicating an accelerated
progress of unfolding with complete denaturation at 468C.
In summary, we observed facilitated unfolding upon
thermal stress of various degrees in all variants, but also
partial unfolding/misfolding in the ground state for some var-
iants. The variant Y133H disclosed signs of severe impairment
of structural integrity consistent with the ﬁndings from the
other stability experiments.
Functional and conformational impact of amino acid
replacements on 3D networks of side-chain interactions
Our experiments revealed severe functional and structural
impairment, in particular, for the variants Y133H, R181C
and R388S. To gain further insights into how these mutations
exert their deleterious effects on the protein, we used a 3D
structural model of the porcine MCAD tetramer to investigate,
whether the amino acid residues affected are involved in net-
works of side-chain interactions with functional and confor-
mational impact.
Residue Y133 maps to the b-sheet domain (residues 130–
239) and is an essential part of the active site (Fig. 5A). It
directly interacts with the cofactor FAD via hydrogen bond
formation. Its aromatic side-chain points towards the hydro-
phobic core of the deep binding cavity for the fatty acid
portion of the substrate establishing hydrophobic interactions
with the residues L103, V135, F177, A248 and F252 which
Figure 3. Variant MCAD proteins show early thermal inactivation and
reduced kinetic stability. The effect of thermal stress on enzyme activity of
wild-type (WT) and variant MCAD was analyzed. (A) Thermal inactivation
proﬁles. Proteins were incubated at increasing temperatures (25–558C) and
the residual enzyme activities were determined. All variants showed a left-
shift of the curves in comparison to WT indicating an inactivation of the
enzyme at lower temperatures (Table 4, left panel). (B) Kinetic stability at
418C. Proteins were incubated at 418C and the residual enzyme activity was
determined at incremental time points. For all variants, steeper slopes of the
curves were observed indicating a reduction of half-lives compared with
WT (Table 4, right panel). Data points of residual activities in both datasets
were normalized to the initial enzyme activity and subjected to non-linear
regression analysis. Error bars represent the mean+SEM of n ¼ 3 indepen-
dent experiments.




Thermal inactivation Kinetic stability at 418C
T1/2
(8C)
SEM P-value t1/2 (min) SEM P-value
WT 44.5 0.45 20.0 2.36
A27V 39.8 0.88 ,0.05 11.8 2.28 ns
Y42H 39.8 0.52 ,0.05 12.7 1.35 ns
Y133H 33.6 1.01 ,0.01 6.1 1.14 ,0.01
R181C 34.3 1.28 ,0.01 6.8 0.88 ,0.01
D241G 33.9 1.08 ,0.01 9.7 0.91 ,0.05
K304E 40.6 0.43 ns 12.8 2.53 ns
R309K 38.8 1.80 ,0.01 12.9 1.57 ns
R388S 42.0 0.37 ns 15.7 0.59 ns
Thermal inactivation and kinetic stability of wild-type (WT) MCAD were
compared with variant MCAD proteins. For thermal inactivation, residual
activities at different temperatures (25–558C) were subjected to
non-linear regression analysis and the midpoints of thermal inactivation
(T1/2) were calculated. T1/2-values represent the temperature at 50%
residual activity and are given in degree Celsius as means with the
corresponding standard errors of the mean (SEM) of n ¼ 3 independent
experiments. For kinetic stability, the inactivation at 418C was determined
as a function of time. The residual activities were subjected to non-linear
regression analysis and the half-lives (t1/2) were calculated. t1/2-values
represent the time point at 50% residual activity and are given in minutes
as means with the corresponding standard errors of the mean (SEM) of at
least n ¼ 3 independent experiments. Signiﬁcances for the differences
between wild-type and the variants were calculated by one-way ANOVA
and a Dunnett’s post test. (ns, not signiﬁcant).
1616 Human Molecular Genetics, 2009, Vol. 18, No. 9line the cavity. To poise the Ca–Cb bond of the fatty acid for
dehydrogenation, it is sandwiched between the re-face of the
isoalloxazine moiety of FAD and the catalytic base E376. A
replacement of the large, hydrophobic tyrosine by the
smaller, positively charged histidine is supposed to distort
the hydrophobic packing of the binding cavity and by this to
lead to a conformational rearrangement of the active site
pocket. As a result, the correct 3D arrangement of FAD, the
Ca–Cb bond of the substrate and the catalytic base E376
will be impaired leading to the marked disturbance in
enzyme function. Moreover, A248 and F252 are located
within the a-helix G. Interactions between a-helices G and
H in one subunit of the dimer and a-helices I and K in the
opposite unit of the adjacent dimer are known to promote
MCAD tetramer assembly from dimers. Hence, conformation-
al alteration of the substrate binding cavity with impairment of
the helix–helix interactions due to the Y133H substitution
might explain the observed distortion of the oligomeric state.
R181islocatedatthebeginningofanextendedloopstructure
(residues 181–193) at the surface of the protein that connects
b-sheets 4 and 5 (Fig. 5B). The loop contributes to the crevice
shapingtheentrancetotheactivesiteand,duetoitsstronginter-
actions with the beginning of the C-terminal a-domain, plays a
pivotal role for MCAD tetramerization. R181 networks with
D183,D185,K187andA188topoisetheloopinitsproperstruc-
tural conformation. It is well conceivable that the severe struc-
tural distortion of the protein with reduced stability and
impairedtetramerassemblyshownforR181Cisduetoadisrup-
tion of this network caused by the replacement of arginine by a
small, polar, uncharged amino acid.
R388 maps to the end of the C-terminal a-domain (residues
240–396) and is part of an interface of two subunits that
deﬁne a funnel-shaped crevice, the entrance to the active site
mentioned above (Fig. 5C). It is shaped by a-helix K and
the loops among b-sheets 4 and 5, a-helices H and I and
a-helices G and H of the adjacent subunit. R388 forms a
hydrogen bond to the AMP portion of the CoA moiety and
is part of a side-chain network comprising both hydrogen
bonds and electrostatic interactions with the neighboring resi-
dues E389 and R324 in the loop between a-helices H and
I. A substitution of the large, basic, positively charged arginine
by serine might disrupt this network by introducing a gap in
the 3D structure of the crevice. This conformational rearrange-
ment at the entrance to the active site will hinder the accessi-
bility of the substrate octanoyl-CoA and the interaction with
the AMP portion of the CoA moiety. This is in line with our
observation that R388S displays a signiﬁcant decrease in sub-
strate afﬁnity for octanoyl-CoA.
DISCUSSION
NBS for MCADD has revealed an increasing number of mis-
sense mutations that have never been identiﬁed in clinically
diagnosed patients and we have previously described eight
Figure 4. Variant MCAD proteins show accelerated thermal denaturation and
partial protein unfolding in the ground state for some variants. Thermal
unfolding of wild-type (WT) and variants monitored by ANS ﬂuorescence.
(A) ANS ﬂuorescence proﬁles of wild-type, Y133H, R181S and K304E. Inten-
sities of the ﬂuorescent dye ANS, which binds to hydrophobic groups of the
protein presented upon unfolding, are plotted as a function of increasing temp-
eratures. Ground-state ﬂuorescence was markedly increased for Y133H and, to
a lesser extent, for R181C and K304E indicating an increased hydrophobicity
due to partial unfolding of these variants already in the native state. (B)
Thermal denaturation of all variants analyzed. Fractions of unfolded protein
are plotted as a function of increasing temperatures and the transition mid-
points represent the temperature at half denaturation (fraction unfolded 0.5).
All variants showed a marked to moderate left-shift of the curves implying
an increased propensity to unfold upon thermal stress (Table 5). In addition,
Y133H showed accelerated unfolding as indicated by the steeper slope of
the curve and complete denaturation at 468C.
Table 5. Transition midpoints of thermal denaturation of wild-type and variant
MCAD proteins
Missense mutation Tm1/2 (8C) SEM P-value
WT 52.6 0.40
A27V 48.8 0.69 ,0.01
Y42H 50.1 0.19 ,0.01
Y133H 42.2 0.11 ,0.01
R181C 40.0 0.16 ,0.01
D241G 46.4 0.65 ,0.01
K304E 48.2 0.16 ,0.01
R309K 50.0 0.14 ,0.01
R388S 47.0 0.85 ,0.01
Transition midpoints of thermal denaturation obtained by ANS
ﬂuorescence of wild-type (WT) MCAD were compared with variant
proteins. Three sets of independent experiments were performed. The
transition midpoints (Tm1/2) were calculated by non-linear regression
analysis and are given in degree Celsius as means with their corresponding
standard errors of the mean (SEM). Signiﬁcances for the differences
between wild-type and variants were calculated using one-way ANOVA
followed by a Dunnett’s post test.
Human Molecular Genetics, 2009, Vol. 18, No. 9 1617of these mutations identiﬁed in the Bavarian NBS program (3).
Since clinical management protects patients diagnosed by
NBS from sequels of catabolic stress, the clinical risk associ-
ated with this particular set of mutations still remained
unclear. The question, whether patients carrying these
mutations might be at lower or no risk of experiencing meta-
bolic decompensation is therefore a matter of controversial
debate, and concern has been raised on whether NBS creates
unwarranted anxiety in parents and health-care professionals
(21,28). To address this issue, we analyzed the corresponding
recombinant variant proteins aiming (i) to evaluate whether
the mutations are genuinely pathogenic, (ii) to assess the
severity of the mutation’s impact and (iii) to elucidate the mol-
ecular mechanisms of loss-of-function. Having applied comp-
lementary strategies, we provide several lines of experimental
evidence that all novel missense mutations identiﬁed in our
NBS lead to protein misfolding with severe impact on struc-
tural conformation, protein stability and to a lower extent,
on enzyme kinetics. Thus, our results support the hypothesis
that MCADD adds to the growing catalogue of protein mis-
folding disorders with loss-of-function. Moreover, the exper-
imental data do not support the view that novel mutations
found in NBS bear a lower risk of metabolic decompensation
than that associated with mutations detected in clinically
ascertained patients, but this remains a possibility.
Two variants showed a complete loss of protein function
due to aggregation (I331T) and degradation (R223G), respect-
ively. Most remaining variants necessitated co-overexpression
of GroESL for tetramer assembly. Only R388S formed into
Figure 5. Functional and conformational involvement of amino acid residues
affected by MCAD mutations in networks of side-chain interactions. Selected
parts of subunit backbones are shown as ribbon representations. Selected resi-
dues are depicted as stick models with carbon atoms in white, oxygen atoms in
red and nitrogen atoms in blue. Hydrogen bonds and electrostatic interactions
are shown as golden dotted lines. The cofactor FAD and the substrate analog
3-thiaoctanoyl-CoA are shown in yellow and in purple, respectively. (A)
Residue Y133 is located at the beginning of the b-domain of the protein
(subunit A, blue). It is part of the active site crevice by binding the isoallox-
azine ring of FAD, together with T136 and T168. The aromatic side chain of
Y133 establishes hydrophobic interactions with A100, L103, P107, V135,
F177, A248, F252 and V259. These residues shape the hydrophobic core of
the deep binding cavity for the fatty acid portion of the substrate. The
precise three-dimensional arrangement of FAD, the Ca–Cb bond of the sub-
strate and the catalytic base E376 is the basis for enzyme function. Moreover,
the structural integrity of the hydrophobic core of this cavity is crucial for the
assembly of tetramers from dimers by four-helix bundle interactions between
a-helices G and H in one subunit (subunit A, blue) and a helices I and K in the
opposite unit of the adjacent dimer (subunit D, red). (B) The guanidinium side-
chain of R181 adopts a central position in the extended loop structure (residues
182–193) at the surface of the protein that connects b-strands 4 and 5 (subunit
A, blue). R181 networks with loop residues D183, D185, K187 and A188 via
hydrogen bonds, and this contributes to the correct spatial conformation of the
loop. The neighboring S182 interacts with T195 in b-strand 5, which estab-
lishes interactions to the loop (residues 239–244) interconnecting the
b-domain with the C-terminal a-domain. The following a-helix G is part of
both the hydrophobic core of the active site and the four-helix bundle
between a-helices G and H in one subunit (subunit A, blue) and a-helices I
and K in the opposite unit of the adjacent dimer (subunit D, red) assembling
the tetramer. The active site is represented by the cofactor FAD interacting
with Y133, T136 and T168, the Ca–Cb bond of the substrate, and the catalytic
base E376. (C) Residue R388 is located in the C-terminal a-helix K and is part
of an interface between two subunits forming the dimer (subunit A, blue;
subunit B, yellow). The interface deﬁnes a funnel-shaped crevice, the entrance
to the active site. Subunit A (blue) lines the crevice with a-helix K and the
loops between b-strands 4 and 5 (containing R181) and a-helices H and
I. The adjacent subunit B (yellow) contributes to the interface via the loop
between a-helices G and H. R388 joins a network of hydrogen bonds and elec-
trostatic interactions comprising residues E389, R324, N325, D253 and S191,
which bind the CoA moiety of the substrate to the entrance of the active site
(subunit A, blue). R281 and T283 in the adjacent subunit (subunit B, yellow)
interact with the pyrophosphate and the adenine ring of the cofactor FAD.
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chaperonins. The ﬁndings of increased propensity of variant
MCAD proteins to form aggregates in Escherichia coli and
partial rescue by increasing the amount of available chapero-
nins was regarded as a ﬁrst evidence for misfolding. Although
co-overexpression of GroESL can assist to overcome protein
misfolding in terms of aggregation and by this promote the
formation of correctly assembled oligomers (29), it does not
correct for the mutation induced structural defects of the
variant protein. These defects were then analyzed in detail in
this study.
All puriﬁed tetrameric MCAD variants revealed alterations
of structural conformation, yet of various degrees. Interest-
ingly, all variants showed thermal instability. Thermal unfold-
ing was accelerated with a shift of the transition midpoint
(wild-type, 52.68C) by .48C in most variants and down to
408C in variant R181C. Thermal inactivation experiments
revealed a 50% loss-of-function at temperatures ,408C (wild-
type 44.58C) in all variants except for K304E and R388S. This
observation is of particular interest, since in a considerable
share of patients with MCADD metabolic decompensation
occurs during intercurrent illness with fever. These ﬁndings
are in line with the previous data on thermal stability of
other variant MCAD proteins (14–16,21,22). Moreover, we
observed that thermal instability was most pronounced in var-
iants mapping to the b-sheet domain of the protein (Y133H,
R181C) or to the loop interconnecting this domain and the C-
terminal a-helix domain (D241G).
Additional evidence for protein instability arose from our
data on limited proteolysis. Most variants showed an increased
susceptibility against proteolytic attack indicating disturbed
folding kinetics (i.e. shift of the folding equilibrium towards
the unfolded state) and local unfolding. Mild alterations
were observed in variants derived from mutations located in
the tightly packed C-terminal a-domain. Again, the variants
mapping to the b-sheet domain and its subsequent loop dis-
closed the most pronounced alterations consistent with
severe conformational changes.
In two variants located in the b-sheet domain (Y133H and
R181C), severe alterations of protein conformation were
evident even without thermal or proteolytic stress. Elevated
ground state ANS ﬂuorescence revealed an increase in hydro-
phobicity and thus a shift to the non-native state of these pro-
teins. In Y133H, the induced conformational changes led to a
severe destabilization and almost complete loss-of-function
with a residual catalytic activity of 3.5%. The affected
amino acid residue Y133 is part of the active site in two
respects. Together with T136 and T168, it anchors the
co-factor FAD to the protein via hydrogen bonds. In addition,
the aromatic side chain of Y133 contributes to the hydro-
phobic core lining the binding cavity for the fatty acid. Pre-
vious studies characterizing the molecular phenotype of
T168A (c.577A.G), a mutation that has been identiﬁed in a
clinically diagnosed patient, are in line with our observations
revealing misfolding, markedly decreased thermal stability
and catalytic activity (15,16,18). In contrast, R181C showed
a residual catalytic activity comparable to wild-type despite
its severe conformational alterations. Our data are consistent
with the notion that the major molecular basis for the patho-
genesis of this variant in vivo may be protein instability
under physiological stress pointing to a high risk of metabolic
decompensation during times of illness, especially associated
with fever. As previously reported, a patient homozygous for
this mutation showed remarkably mild biochemical alterations
in NBS (3), although a mutation affecting the same amino acid
residue (R181L; c.617G.T) was identiﬁed in two sympto-
matic patients (30). Our experimental data emphasize that
mild biochemical alterations in NBS do not allow implying
a low risk for decompensation.
Mutations located in the N-terminal a-domain showed mod-
erate effects on tetramer assembly and thermal stability
together with decreased (A27V) or normal catalytic activity
(Y42H). Consistent with our ﬁndings, mutations located in
this region have previously been described as mild folding var-
iants with normal activity (M124I; c.447G.A), medium
range activity (R28C; c.157C.T) or moderate thermal
instability (Y42H) (10,21). However, a-helices A, C and D
of this domain form the recognition site of the electron transfer
ﬂavoprotein, which is the natural electron acceptor of the
MCAD protein and responsible for the electron transfer to
the respiratory chain (31). Whether structural changes in this
domain result in an alteration of electron transfer rates
remains to be elucidated.
In contrast, mutations located in the C-terminal a-domain
(K304E, R309K, I331T) often affect helix–helix interactions
crucial for tetramer assembly leading to aggregation
(10,12,13,22,23). However, when aggregation was overcome
by co-overexpression of chaperonins, these variants showed
considerable residual activities. Interestingly, R388S, also
located in the C-terminal a-domain, was the only variant
that did not require co-overexpression of GroESL for tetramer
formation and its proteolytic and thermal stabilities were only
moderately affected. In this variant, misfolding resulted in a
marked decrease of substrate afﬁnity. Similar effects on Km
have been shown for artiﬁcial variants of the homologous argi-
nine residue R387 of the ACAD isovaleryl-CoA dehydrogen-
ase (32) and have been predicted from crystal structure
analysis for the ACAD glutaryl-CoA dehydrogenase (33).
Our data substantiate the essential role of this highly con-
served arginine residue for binding of the substrate in ACADs.
The observations obtained from analyzing variants harbor-
ing amino acid substitutions in different regions of the
protein show that mutations in the b-sheet domain and the
adjacent loop (interconnecting the b-domain and the
C-terminal a-domain) are particularly instable and prone to
severe conformational distortion. This is in line with the pre-
vious work describing severely impaired biogenesis and stab-
ility for two other variants located in the b-domain, T168A
and G170R (c.583G.A) (10,15). Misfolding observed in
these variants has been attributed to the loss of FAD anchor-
ing, which has been reported to be crucial for folding and oli-
gomerization (34). However, the compiled data including our
variants spread over the b-domain indicate that not only
reduced FAD binding, but also the structural and functional
characteristics of the b-domain itself account for the protein
destabilization observed.
In conclusion, all mutations analyzed in this study showed
signiﬁcant alterations of the molecular phenotype ranging
from mild to severe. Six of the mutations (Y133H, R181C,
R223G, D241G, I331T and R388S) identiﬁed in presympto-
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than the variant K304E, which is generally accepted to be
associated with a severe molecular and clinical phenotype. It
has to be noted, however, that patients homozygous for
K304E may experience a healthy life (2) and our ﬁndings of
a severe molecular phenotype do not unequivocally prove a
severe clinical phenotype. Standard diagnostic procedures
such as the determination of blood acylcarnitine concen-
trations do not allow for a meaningful prediction of the clinical
course. Hence, compiled knowledge gained by documentation
of the clinical and biochemical course of speciﬁc genotypes in
combination with detailed molecular characterization of the
respective variants at the protein level will improve geno-
type–phenotype correlation. This may assist counseling and
risk assessment of MCADD patients identiﬁed in NBS pro-
grams. In this context, it has also to be taken into account
that most patients revealing mutations other than the predomi-
nant K304E are compound heterozygous. Moreover, gene–
gene interactions and gene–environment interactions such as
cellular and environmental conditions or stressors may also
modify the natural course of the disease (35).
A molecular scenario similar to that now identiﬁed for
MCADD was recently described for the phenylalanine
hydroxylase protein, the enzyme deﬁcient in phenylketonuria
(36). In this disease, experimental evidence is now available
that the well proven efﬁcacy of tetrahydrobiopterin (37,38)
is based on a pharmacological chaperone effect. For MCAD,
we and others showed that increasing the amount of available
molecular chaperones (GroESL) prevents MCAD aggregation
and leads to higher amounts of functional protein. The persist-
ing loss-of-function is then predominantly promoted by
instability against thermal or proteolytic stress. Early degra-
dation could thus be overcome using pharmacological chaper-
ones, conceivably in combination with proteostasis regulators
as recently shown for lysosomal storage diseases (39).
In summary, the detailed insight into how ACADM missense
mutations induce conformational alteration and protein desta-
bilization resulting in loss of enzyme function presented here
may in future provide the basis to delineate novel pharmaco-
logical strategies for the potentially fatal MCADD disease.
MATERIALS AND METHODS
Subjects and mutations
In the previous study, we described the spectrum of sequence
variations occurring in newborns with MCADD detected by
NBS (3). We identiﬁed eight novel missense mutations
within the ACADM gene that have not yet been characterized
in vitro: A27V (c.155C.T), Y133H (c.472T.C), R181C
(c.616C.T), R223G (c.742A.G), D241G (c.797A.G),
R309K (c.1001G.A), I331T (c.1067T.C) and R388S
(c.1237C.A) (Table 1). Two mutations (R181C and
R223G) were found in a homozygous state. The two individ-
uals homozygous for R223G displayed markedly elevated bio-
chemical markers, whereas the individual homozygous for
R181C showed only mild alterations. The remaining mutations
were found in a compound heterozygous state with the two
most prevalent mutations Y42H (c.199T.C) and K304E
(c.985A.G). Mutations and biochemical phenotypes of the
patients are summarized in Supplementary Material,
Table S1. The structural localization of mutations character-
ized in this study was mapped to the 3D model of the
porcine MCAD monomer (Fig. 1).
Plasmid construction and site-directed mutagenesis
The cDNA of human ACADM gene (ACADM-encoding
pKK223 plasmid obtained as a generous gift from Jerry
Vockley, Pittsburgh, USA) was cloned into the pMAL-c2X
expression vector (New England Biolabs) encoding a N-
terminal MBP-tag and a factor Xa cleavage site. ACADM
mutations were introduced using the PCR-based QuikChange
Site-Directed Mutagenesis Kit (Stratagene). After mutagen-
esis, all expression vectors were veriﬁed by DNA sequencing.
Expression and puriﬁcation
The expression plasmids were used to transform E.coli strain
BL21-CodonPlus (Stratagene). Bacteria were grown in 2 l of
dYT medium (16 g/l tryptone, 10 g/l yeast extract and 5 g/l
NaCl) containing 100 mg/ml Ampicillin to OD600 0.6–0.8 at
378C. Overexpression of wild-type and variant MBP–
MCAD fusion proteins was induced with 0.01 mM
isopropylthio-b-D-galactoside and performed at a reduced
growth temperature of 288C for 20 h. Bacteria were harvested
by centrifugation and lysed by sonication. Protein puriﬁcation
was performed using A ¨KTApuriﬁer and A ¨KTAprime systems
(GE Healthcare) at 48C. The crude extract/protein sample was
loaded on a MBPTrap afﬁnity chromatography column (GE
Healthcare) equilibrated with column buffer (20 mM Tris–
HCl pH 7.4, 200 mM NaCl, 1 mM EDTA, 1 mM DTT) and
eluted with the same buffer containing 10 mM maltose after
washing out unbound bacterial protein. The eluted protein
fractions were pooled and subjected to SEC using a HiLoad
16/60 Superdex 200 column (GE Healthcare) equilibrated
with 20 mM HEPES pH 7.0 containing 200 mM NaCl. The
fractions containing tetrameric fusion proteins were pooled
and incubated for 12 h at 48C with factor Xa (Novagen) to
cleave the MBP-tag of the fusion proteins at a protease to
fusion protein ratio (U:mg) of 1:20. Final puriﬁcation of the
cleaved tetrameric MCAD protein was obtained by SEC on
a HiLoad 16/60 Superdex 200 column (GE Healthcare) equi-
librated with 20 mM HEPES pH 7.0 containing 200 mM
NaCl and reached a purity of .98% SDS/PAGE analysis.
Protein concentrations were determined spectrophotometri-
cally using the absorption coefﬁcients at A272 and A448 (14), or
the ﬂuorescent dye binding Quant-iT assay (Invitrogen). Using
this approach, up to 14 mg of cleaved MCAD tetrameric
protein of high purity (.97%) were obtained from 2 l
culture. A summary of the puriﬁcation protocol is given in
Supplementary Material, Table S2.
Co-overexpression of chaperonins GroESL
The respective pMAL-c2X MCAD expression plasmids were
co-transformed with pGroESL encoding the proteins GroES
and GroEL (40) in E.coli strain DH5a (Invitrogen). Growth
of bacteria, expression and puriﬁcation of proteins were
performed as described above except for the addition of two
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(50 mg/ml), to the broth.
Analysis of oligomerization
MCAD oligomerization was analyzed by SEC of the MBP–
MCAD fusion proteins prior to cleavage with factor Xa. The
MBP-tag increases solubility and yield during expression,
but does not signiﬁcantly affect the oligomeric state of the
expressed proteins [own and previous observation (41)]. The
size-exclusion column was calibrated using low molecular
weight and high molecular weight gel ﬁltration calibration
kits (GE Healthcare). Blue dextran was used to determine
the void volume (V0, 46.0 ml).
Analyses of enzyme kinetic parameters
MCAD activity was determined using the ferricenium-based
spectrophotometric assay described previously (42). Measure-
ments were performed in 100 mM HEPES, pH 7.6, containing
0.1 mM EDTA at a temperature of 258C with increasing con-
centrations of octanoyl-CoA (Sigma Aldrich, Larodan Chemi-
cals) ranging from 0 to 20 mM (150 mM for the Km variant). In
order to correct for varying qualities of octanoyl-CoA with
respect to the degree of purity, amount of crystal water and
cationic ligands provided by the manufacturers, concentrations
of oxidizable substrate were determined by complete turn-over
using an excess of enzyme and electron acceptor. All measure-
ments were corrected for background reduction of ferricenium.
The assays were performed in at least three independent
experiments. The kinetic parameters Km and Vmax were aver-
aged after non-linear regression analysis using the Michae-
lis–Menten algorithm implemented in pro Fit (QuantumSoft).
Limited proteolysis by proteinase K
Five micrograms of the puriﬁed tetrameric MCAD proteins
were incubated with proteinase K (Sigma) using two different
protease to substrate ratios, 1:1 and 1:25 by weight. The exper-
iments were performed at 378Ci n2 0m M HEPES buffer pH
7.0 containing 200 mM NaCl. Proteolysis was terminated at
time points 2, 4, 6, 8, 10, 20, 30, 60 and 120 min by the
addition of the inhibitor phenylmethylsulphonyl ﬂuoride at a
ﬁnal concentration of 0.4 mM. The protein samples were sub-
jected to SDS–PAGE under reducing conditions using 4–12%
gradient polyacrylamide gels (Invitrogen). Proteolysis was
monitored by Coomassie staining and subsequent densitome-
try analysis. Densitometry data were quantiﬁed by AIDA-
software (Raytest), normalized to the intact MCAD protein
prior to proteolysis and analyzed by non-linear regression.
The experiments for each protease to substrate ratio were per-
formed in triplicates. Signiﬁcances for the differences between
wild-type and variant proteins concerning plateau of proteol-
ysis (protease to substrate ratio 1:1) and half-lives (protease
to substrate ratio 1:25) were calculated using one-way
ANOVA followed by a Dunnett’s post test. Using the substrate
ratio of 1:25 resulted in a slower decline of protein and, thus,
was more suitable to determine half-lives.
Thermal inactivation experiments
To determine the effect of various temperatures on MCAD
activity, aliquots of protein (5 mg/ml) were incubated in
100 mM HEPES, pH 7.6 containing 0.1 mM EDTA for
15 min at 11 different temperatures ranging from 25 to
558C, and then chilled on ice. Enzyme activity was sub-
sequently measured at an octanoyl-CoA concentration of
10 mM as described above. Residual activities were normalized
to initial enzyme activity at 258C.
For the assessment of thermal effects over time, one aliquot
of protein (5 mg/ml) was incubated at 418C with enzyme
activities being determined at nine incremental time points
(5–120 min). Residual activities were normalized to enzyme
activity prior to incubation.
Data points were subjected to non-linear regression
analysis and midpoints of thermal inactivation (T1/2) and
half-lives (t1/2) were calculated; T1/2 indicates the temperature
and t1/2 marks the time at 50% residual activity, respectively.
Measurements were performed in three independent exper-
iments. Signiﬁcances for the differences in T1/2 and t1/2
between wild-type and variant proteins were calculated
using one-way ANOVA followed by a Dunnett’s post test.
Thermal denaturation monitored by ANS ﬂuorescence
Fluorescence measurements were performed on a Cary Eclipse
ﬂuorescence spectrophotometer equipped with a temperature-
controlled Peltier multicell holder (Varian). Samples con-
tained MCAD proteins (11.6 mM MCAD subunit) in 20 mM
HEPES buffer at pH 7.0 containing 200 mM NaCl. The dena-
turation was monitored following the changes in ANS (pur-
chased from Sigma) ﬂuorescence emission: excitation at
395, emission at 450 nm (5.0/10.0 nm slit widths). The dena-
turation was performed at a rate of 1.28C/min from 20 to
358C and from 70 to 858C and at a rate of 0.38C/min from
35 to 708C in three independent experiments. The transitions
midpoints (Tm1/2), indicating the temperature at 50% denatura-
tion, were calculated by the differentiation of the increasing
part of the curves. Signiﬁcances for the differences between
wild-type and variants were calculated by one-way ANOVA
and a Dunnett’s post test.
Statistical analyses
Non-linear regression analyses and statistical tests were per-
formed using GraphPad Prism 4.0c (GraphPad Software).
Structural analyses and ﬁgure preparation
The 3D structure of tetrameric pig MCAD complexed with the
substrate analog 3-thiaoctanoyl-CoA (PDB code 1UDY) was
analyzed using the DeepView-Swiss-PdbViewer (43). The
porcine MCAD protein shows a .90% homology with
human MCAD, and only homologous amino acid residues
have been analyzed. In the presence of hydrogen atoms,
H-bonds were computed with the following constraints: 1.2–
2.76A ˚ distance, 1208 angles. When hydrogen atoms were
absent, interactions were computed with the following
Human Molecular Genetics, 2009, Vol. 18, No. 9 1621constraints: 2.35–3.2A ˚ distance, 908 angles. Figures were pre-
pared using VMD (44).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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